polyhydramnios and fetal hydrops. Adverse postnatal outcomes are respiratory symptoms that require oxygen, needs for mechanical ventilation and undergoing non-elective surgery within 30 days after birth. Results: A total of 160 fetuses were confirmed as CCAM; 159 (99%) survived, 29 (18%) had respiratory symptoms requiring oxygen, and 18 (11%) received intubation. A total number of 58 (36%) of the survivors underwent surgery; 20 (34%) of these surgeries were non-elective within 30 days after birth, while 38 (66%) surgeries were performed electively in asymptomatic patients at a median age of 26 months (range, 23-29 months). All prenatal ultrasonographic features were significantly associated with the adverse postnatal outcomes. The median CVR at diagnosis was 0.78 (range, 0.41-1.16). The optimal cut-off values of CVR for predicting respiratory symptoms that require oxygen, needs for mechanical ventilation, and undergoing non-elective surgery within 30 days after birth were 0.97, 0.97, and 0.96, respectively. Conclusions: In addition to predictive factors that are already known, the CVR can be an additional marker for predicting postnatal adverse outcomes of CCAM. Objectives: There is a change in surveillance of growth restricted fetuses, from umbilical artery (UA) Doppler to brain sparing. This is based on the perception that there are no abnormal UA Doppler tracings in late pregnancy and that moderate small-forgestational-age (SGA) pregnancies (-2 SD to -2.5 SD) with normal UA Doppler have worse prognosis as compared to appropriatefor-gestational-age (AGA) pregnancies. According to the brain sparing algorithm, more pregnancies are abnormal and earlier delivery is recommended. Methods: A secondary analysis of a historical prospective cohort including 25,875 pregnancies was performed. Identified SGA fetuses (n=681) the lowest 2.5 th centile, were compared with AGA fetuses (n=24,622). The overall risk of severe adverse fetal outcome was defined as a compound of: hypoxic encephalopathy grade 2 or 3, intracranial hemorrhage, cerebral palsy, mental retardation, Apgar score < 4 at 5 min, umbilical pH < 7.0, neonatal convulsions, stillbirth, or infant death. Main outcome is if the basis (see above) for a changed surveillance of growth restriction is correct. Results: Identified SGA pregnancies were delivered one week earlier than unidentified (38+0 vs. 39+0 weeks) and both the proportion of elective and emergency Caesarean deliveries were ≈10% higher among identified SGA pregnancies. Identified moderate SGA pregnancies (-2 SD to -2.5 SD) with normal UA Doppler surveilled with estimated fetal weight, CTG, had a similar risk as AGA pregnancies. From 36 to 42 weeks of gestation the proportion of abnormal UA Doppler tracings decreased from 44.2% to 9.4%, and there was only one stillbirth (1/472 or 0.2%). The risk of severe adverse fetal outcomes was increased by 50% for delivery each week before 38 gestational weeks.
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OC24: FETAL GROWTH
Conclusions: Before a change in surveillance method for growth restriction is implemented, a randomised validation like the Truffle 2 study is needed. There is a risk that increased prematurity will counterbalance any benefits. Objectives: Maternal and fetal Doppler changes are seen in fetal growth restriction (FGR) and/or pre-eclampsia (PE). These have been attributed to defect in the maternal placenta circulation. There is increasing evidence that maternal cardiovascular function is abnormal in these conditions. We sought to determine whether maternal cardiovascular hemodynamics were related to uterine artery (UtAD) and fetal umbilical artery Doppler (UAD) changes in healthy and complicated pregnancy. Methods: Women between 24-40 weeks gestation were prospectively recruited into 4 groups-pre-eclampsia (PE), fetal growth restriction (FGR), fetal growth restriction with pre-eclampsia (PE+FGR) and healthy pregnancies (control). PE was defined as blood pressure at diagnosis of > 140/90 mmHg and urine protein creatinine ratio> 30. FGR was defined as fetal abdominal circumference < 10th percentile and UAD PI > 95th percentile. Those with chronic hypertension, multiple pregnancy or fetal anomaly were excluded. Maternal cardiac output was assessed with Innocor, an inert gas non-rebreathing technique and peripheral vascular resistance derived. Mean UtAD PI and fetal UAD PI were recorded. Indices that changed with gestation were transformed with z-scores. Polynomial regression analyses were undertaken to determine relationships. Results: There was a negative relationship between UtAD PI and CO (r 2 =0.101; p=0.025) and UAD PI and CO (r 2 =0.078; p=0.015), and positive associations between UtAD PI and PVR (r 2 =0.150; p=0.003) and UAD PI and PVR (r 2 = 0.145; p=0.001). Conclusions: There is a significant relationship between maternal CO and PVR and Doppler impedance in both the utero-placental and fetal-placental circulations in normal and pathological pregnancy outcome: lower CO and higher PVR being associated with increased UtA and UAD impedance. This finding suggests a hitherto unrecognised link between maternal cardiovascular function and fetal wellbeing with potentially important implication for late pregnancy surveillance and therapeutic options in pathological pregnancies. 
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